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An aneurysm is a local dilatation of a vessel wall which is >50% its original diameter.
Within the spectrum of cardiovascular diseases, aortic aneurysms are among the
most challenging to treat. Most patients present acutely after aneurysm rupture or
dissection from a previous asymptomatic condition and are managed by open surgical or
endovascular repair. In addition, patients may harbor concurrent disease contraindicating
surgical intervention. Collectively, these factors have driven the search for alternative
methods of identifying, monitoring and treating aortic aneurisms using less invasive
approaches. Non-coding RNA (ncRNAs) are emerging as new fundamental regulators
of gene expression. The small microRNAs have opened the field of ncRNAs capturing
the attention of basic and clinical scientists for their potential to become new therapeutic
targets and clinical biomarkers for aortic aneurysm. More recently, long ncRNAs
(lncRNAs) have started to be actively investigated, leading to first exciting reports,
which further suggest their important and yet largely unexplored contribution to vascular
physiology and disease. This review introduces the different ncRNA types and focus at
ncRNA roles in aorta aneurysms. We discuss the potential of therapeutic interventions
targeting ncRNAs and we describe the research models allowing for mechanistic studies
and clinical translation attempts for controlling aneurysm progression. Furthermore, we
discuss the potential role of microRNAs and lncRNAs as clinical biomarkers.
Keywords: microRNAs, long non-coding RNAs, aneurysms, vascular cells, therapeutic targets, biomarkers
Introduction
Arterial aneurysms (AAs) are asymmetrical dilatations of arterial wall, most commonly found
in the infra-renal abdominal aorta (see Figure 1). Lesions develop when intraluminal pres-
sures exceed the capacity of the arterial wall which has developed a localized weakness. It
is estimated that abdominal aortic aneurysms (AAA) account for approximately 2–4% of all
deaths in men aged 65 and over (Clouse et al., 1998; Booher and Eagle, 2011). Thoracic aortic
Abbreviations: AA, arterial aneurysm; AAA, abdominal aorta aneurysm; Ang II, angiotensin II; ANRIL, antisense non-
coding RNA in the INK4 locus; ARF, alternate reading frame; BAV, bicuspid aortic valve; BRG, Brahma-related gene; DOCK:
dedicator of cytokinesis; EC, endothelial cell; ECM, extracellular matrix; ELN, elastin; ERK, extracellular-signal-regulated
kinase; HIF, hypoxia-inducible factor; JNK, c-Jun NH(2)-terminal kinase; KLF, Krüppel-like factor; lncRNA, long non coding
RNA;miRNA,miR, microRNA;MMP,matrix metalloproteinases; ncRNA: non coding RNA; PPE, porcine pancreatic elastase;
PTEN, Phosphatase and tensin homolog; rRNA, ribosomal RNA; SMC, smooth muscle cell; SnoRNA, small nucleolar RNA;
SNP, single nucleotide polymorphism; TAA, thoracic aortic aneurysm; TIMP, tissue inhibitors of metalloproteinase; TGFβ,
transforming growth factor β; TNFα, tumor necrosis factor α; tRNA, transfer RNA; VSMC, vascular smooth muscle cell.
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FIGURE 1 | A computed tomography (CT) scan with contrast showing
an abdominal aortic aneurysm. This aneurysm was asymptomatic and
found during routine surveillance scanning of a 67 year old male. Calcified
atherosclerotic plaque is noted on the aneurysm wall and in the distal aorta (a).
aneurysms (TAAs) (Figures 2, 3) represent themost lethal site for
a dilatation. They may remain asymptomatic for years and man-
ifest as an acute rupture or dissection which can be fatal if left
untreated. The prevalence of thoracic aneurysms in the United
States is estimated at 10.4 per 100,000 people (Clouse et al., 1998).
TAAs is a silent disease and 95% of cases present acutely from
previously asymptomatic patients (Clouse et al., 1998). Thoracic
aortic aneurysms are classified according to the segment of the
dilatation. This anatomical classification is important because
the etiology, natural history and treatment may differ for each
segment.
The ascending thoracic aorta and the descending/abdominal
aortas have different embryological aetiologies, pathological
features and their evolution progresses differently (better
described below—Section Mechanisms Underlying Abdominal
Aortic Aneurysms). Aneurysms are much more common in
the abdominal aorta than in the ascending aorta. Classically,
atherosclerosis has been considered the underlying cause of
abdominal aortic aneurysms (Lederle et al., 1997; Guo et al.,
2001). Known cardiovascular risk factors mostly associated with
AAA include smoking, increasing age, hypertension, hyper-
lipidaemia which predispose to atherosclerosis (Lederle et al.,
1997; Coady et al., 1999). On the other hand, atherosclerosis is
infrequently implicated in ascending thoracic aortic aneurysm
development. Ascending thoracic aneurysms are associated with
FIGURE 2 | Ascending aortic aneurysm. This is an aorta of a 37 year old
male who was found to have a 7.7 cm saccular ascending aortic aneurysm
associated with a leaking bicuspid aortic valve. The remainder of the aorta is
normal caliber. (A) CT reconstruction of the whole aorta with ascending aortic
aneurysm (a), with a normal caliber abdominal aorta (b). (B) Surgical view of
this aneurysm; (C) Dacron graft after surgical replacement.
hypertension, connective tissue disease, bicuspid aortic valves,
familial thoracic aneurysm syndrome, (Coady et al., 1999; Guo
et al., 2001; Nuenninghoff et al., 2003; Demers et al., 2004).
This review focuses on non-coding (nc) RNAs as possible new
mechanisms of diagnosis and monitoring of aneurysmal disease
and novel therapeutic enabling to control the progression to dis-
section and rupture. The recent advancement in DNA and RNA
sequencing techniques have led to the understanding that around
98% of the human genome contains regions of DNA which code
for RNAmolecules unable to produce proteins and hence termed
ncRNAs. Far from being “junk RNA,” many ncRNAs are prov-
ing to be very powerful regulators of gene expression, acting at
both transcriptional and post-transcriptional level. ncRNAs are
arbitrarily defined accordingly to their size, as small ncRNAs and
long ncRNAs (lncRNAs). MicroRNAs (miRNAs, miRs) are the
most popular small ncRNAs. Here, we will review miRNA and
lncRNAs for their regulatory roles in vascular function, with spe-
cial attention to their contribution to VSMC function and vas-
cular degenerative disease. Finally, we will discuss the potential
of ncRNAs as new therapeutic targets and clinical biomarkers
to be employed in patients with aneurysms at different stage of
evolution.
Non-Coding RNAs
About 2% of the eukaryotic genome contains protein coding
genes and the remaining DNA was previously supposed to be
“junk DNA,” i.e., DNA devoid of any functional importance.
In fact, large-scale analyses of mammalian transcriptomes have
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FIGURE 3 | Thoracic aorta aneurysms. MRI scans of the ascending
aorta in a 17 year old girl with multiple thoracic aortic aneurysms. In
(i), it is clearly visible a large saccular aneurysm of the aortic arch just
distal to the right carotid artery (RCA) and a second large saccular
aneurysm in the descending aorta. In (ii), the MRI scan shows the
ascending and descending aorta. The left subclavian artery (LSA)
comes off the descending aorta in between two large saccular
aneurysms.
identified 60% of RNA molecules that are not translated into
protein. However, the use of new sequencing technologies has
identified that most of the genome is transcribed, producing
a heterogeneous population of “noncoding RNA” (ncRNAs),
which do not hold information for protein translation. Although
ncRNAs do not code for proteins, they play different roles
in regulating gene expression, thus impacting on cell func-
tions. According to their size, ncRNA are classified as “small
ncRNA” (20–200 nucleotides in their mature forms) and “long
ncRNA” (more than 200nt and up to 100 kilobases). Accord-
ing to their function, ncRNAs can also be classified as “house-
keeping” ncRNAs, which are constitutively expressed and crucial
for normal function and cellular viability. These include tRNA,
rRNA, SnoRNA. By contrast, the “regulatory” ncRNAs, which
are important for the transcriptional regulation of genes. In
recent years, several ncRNAs have been found to regulate vascular
pathologies, including aortic aneurysm (thoracic and abdominal)
disease.
MicroRNAs
MiRNAs are post transcriptional regulators of gene expression.
They influence the stability and translation of messenger RNAs
(mRNAs). MiRNA are encoded (often as polycistronic “clus-
ters”) in intergenic region of protein coding genes or by miRNA
genes. MiRNA genes are transcribed by RNA pol lI as capped
and polyadenylated primary miRNA transcripts (pri-mRNA).
The pri mRNA is then processed in two independent steps
by the enzymes Drosha and DICER. Dorsha/DGCR8 cleaves
the pri-miRNA transcript to a 60–100 nucleotide long hairpin
loop which is transported to the cytoplasm where it is fur-
ther processed to mature miRNA, a single stranded of ∼22
nucleotides. This can be incorporated into the RNA-induced
silencing complex (RISC) and mediates gene silencing by affect-
ing the integrity and/or the protein synthesis capacity of the
targeted mRNAs. A miRNA recognize its mRNA targets mRNAs
by the semi complementarity between its “seed sequence” region
and one or more “miRNA binding sites,” usually located in the 3′
untranslated region (3′ UTR) of themRNAs(Gregory et al., 2006).
Long Non Coding RNAs
The RNA transcripts that are longer than 200 nucleotides which
are polyadenylated and are devoid of open reading frames are
defined as lncRNAs. The functional annotation of mammalian
cDNA (FANTOM3) project identified 35,000 of such non cod-
ing transcripts (Amaral et al., 2011). LncRNA are located and
transcribed with the intergenic region of genome by the RNA
PolI enzyme or in some cases by RNA pol III. The majority are
transcribed as complex, interlaced networks of overlapping sense
and antisense transcripts. On the basis of their genomic loci, long
ncRNA (lncRNAs) can be classified onto: (1) Sense lncRNAs,
transcribed from a locus overlapping with protein coding gene;
(2) Antisense lncRNAs loci, that overlap with the antisense strand
of the protein coding gene; (3) Bidirectional lncRNAs, located
on the antisense strand of the protein coding gene; (4) Intronic
lncRNAs, transcribed from introns to protein coding genes; (5)
Long intergenic ncRNAs (lincRNAs), that are not in the proxim-
ity of protein coding gene. LncRNAs display high organ and cell
specificity and are not well conserved across species. They can
be located in the nucleus or in the cytosol and exert actions in cis
and in trans. LncRNAs can regulate different aspects of transcrip-
tion by playing different roles, including acting on transcription
factors (TFs), RNA polII, mRNA processing, splicing and the epi-
genetic machinery (Kapranov et al., 2007; Broadbent et al., 2008;
Mohammad et al., 2008). Additionally, lncRNAs can exert a post-
transcriptional regulation of protein coding genes, for example by
acting as antisenses inhibitors of mRNAs (Kornienko et al., 2013).
Exploratory studies performed on the lncRNA in the cardio-
vascular setting have so far identified a few lncRNA associated
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with cardiovascular diseases. These include MALAT1 (metastasis
associated lung adenocarcinoma transcript 1), LIPCAR (lin-
cRNA predicting cardiac remodeling), CARL (cardiac apoptosis
related lncRNA), MiAT (myocardial infarction–associated tran-
script), HCG22 (HLA complex group 22), Brave heart, CHRF
(cardiac hypotrophy factor), ANRIL (antisense ncRNA in the
INK4 locus), and HIF1A-AS1 (antisense hypoxia inducible fac-
tor 1 alpha antisense RNA), KCNQ1OT (KCNQ1 overlapping
transcript), and SENCR (smooth muscle and endothelial cell-
enriched migration/differentiation-associated lncRNA). Specific
studies looking at lncRNAs in aortic aneurysm are still lack-
ing (Skroblin and Mayr, 2014). Because of the high number of
lncRNAs, research based on predefined lncRNA candidate is not
ideal and next generation sequencing methods will be useful in
exploring lncRNA which can be functionally related with aortic
aneurysms and it might support the identification of lncRNAs
to be investigated as biomarkers for diagnosing sporadic aortic
aneurysms and to follow up aneurysm evolution.
Cellular Mechanisms and Signaling
Pathways Underpinning Aneurysm
Formation and Evolution
The currently available pharmacological approaches are unable
to prevent aneurism progression. Although there is some suc-
cess demonstrated with Angiotensin II (Ang II) receptor blockers
in non-pathological aneurysms in Marfan’s patients (Attenhofer
Jost et al., 2014), this therapeutic approach is not proven to be
effective enough to substitute the need for surgical therapy. This
lack of effective therapies suggests the need for a better under-
standing the molecular mechanisms underpinning aneurysm
pathology and progression. New mechanistic insight should pro-
vide better targets for therapeutic intervention. In this section,
we’ll describe the pathways and cellular mechanisms underlying
aneurysm formation and evolution.
Mechanisms Underlying Abdominal Aortic
Aneurysms
Abdominal aortic aneurysms have been linked to atherosclerosis
and the pathophysiology of this aneurysm has been well stud-
ied (Guo et al., 2006; Shimizu et al., 2006). Histological anal-
yses of human AAA samples revealed the three pathological
hall marks of abdominal aorta aneurysms: leukocyte infiltration,
degradation of extra cellular matrix (ECM) and VSMC depletion
(Guo et al., 2006). Moreover, work on animal models (described
below) confirmed this data and further indicated that abdominal
aneurysm development involves local inflammatory responses
leading to infiltration of macrophages, neutrophils, mast cells
and T and B lymphocytes (Sun et al., 2007). The prominent
inflammatory cells present in aortic tunica media and adventitia
are macrophages. Macrophage infiltration is critical for abdom-
inal aneurysm development, but its contribution has not been
defined. CCR2 (C-C chemokine receptor 2) and myeloid differ-
entiation factor are important formacrophagemediated response
to inflammation. CCR2 deficiency in mouse models attenuates
the severity of the induced aneurysm (Daugherty et al., 2010).
Neutrophils are also present in experimental and human AAA
tissue. L selectin adhesion molecule mediates the trafficking of
neutrophils from plasma to the aortic wall and L selectin attenu-
ates abdominal aneurysm formation in mouse models (Ishibashi
et al., 2004).
The plasma concentration of certain cytokines, such as tumor
necrosis factor alpha (TNF-α), increases in patients with abdom-
inal aneurysm. However, TNF alpha receptor deficiency has no
significant effect on Ang II- induced AAA formation in LDL
receptor deficient atherosclerotic mice. Another cytokine that
plays a critical role is transforming growth factor beta (TGF-β).
Systemic blockade of TGF-β activity was found to increase Ang
II-induced AAA (Wang et al., 2010).
The drug cyclosporin induces TGF- β expression and its
administration stops aneurysm formation in the rat elastase
and mouse calcium chloride models of AAA (Dai et al., 2011).
Interleukin 1β, IL6, IL17, and IL23 are increased in AAA in
human tissue as compared with healthy tissue (Szekanecz et al.,
1994). AAA formation and progression is also mediated by
various proteases, which degrade elastin and collagen present
in the aortic wall. Matrix metalloproteinase-9 (MMP-9) is a
zinc endopeptidase contributing to calcium chloride-induced
aneurysm development inmice (Tanaka et al., 2009). C-JunN ter-
minal kinase (JNK) was found increased in abdominal aneurysms
in murine models. Moreover, a JNK specific inhibitor prevented
the aneurysms formation in these models (Yoshimura et al.,
2005).
Thoracic Aorta Aneurysm Pathology and
Mechanisms
Thoracic aortic aneurysm (TAA) is caused by proteoglycan accu-
mulation, elastic fiber fragmentation, focal or diffuse VSMC
degradation and loss. The pathological changes can result in
excessive degradation of ECM components, leading to the loss
of mechanical strength and integrity, aortic dilation, dissection,
or rupture (El-Hamamsy and Yacoub, 2009). Histopathologi-
cal findings of the aortic wall in patients with ascending aorta
aneurysm reveal the presence of cystic medial necrosis or medial
degeneration. The aneurysm is characterized by disruption of
the lamellar organization of elastic fibers, cyst like lesions within
the tunica media, pooling of proteoglycans, elastin and colla-
gen fiber fragmentation and coagulative necrosis of VSMCs (El-
Hamamsy and Yacoub, 2009). The NOTCH pathway is activated
in fibroblasts and deregulated in VSMCs of patients with tho-
racic aneurysm. However, the Notch signaling is downregulated
in the ascending aorta of patients with bicuspid aortic valve
(BAV) and in abdominal aneurysms. Genetic variation in the
NOTCH1 gene appears to confer susceptibility to ascending aor-
tic aneurysm formation in patients with BAV (McKellar et al.,
2007). More research is needed to clarify the role of the NOTCH
pathway in aneurysms and to elucidate the possibility of targeting
it therapeutically.
NcRNAs in Aneurysms
NcRNAs have become a subject of great interest for vas-
cular biology and medicine. The scientists interested in
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aneurysm disease can combine cell and animal models
and analyses on clinical samples for their ncRNA stud-
ies. Below, we report on the current knowledge and dis-
cuss the importance of research model optimization for future
research.
Table 1 summarized the miRNAs currently known to be
functionally involved and/or expressionally deregulated in AAs.
Table 2 summarized the lncRNAs that have been shown to be
involved with Vbiology and proposes their link to AA.
Vascular Cell Biology
Cell culture experiments on human aortic VSMCs isolated from
clinical tissue samples suggest the role of miRNAs in aortic
aneurysm development. In this article we present the miRNAs
studied in VSMCs. Similar studies on lncRNAs are still lack-
ing. However, we suggest new roles for these ncRNA molecules
based on the results of some pioneers studies in non-aneurysmal
VSMCs (vide infra at LncRNAs).
miRNAs
The VSMC phenotype and behavior is strongly regulated by miR-
NAs. The phenotype of VSMCs can change between a contractile
to a synthetic state and vice versa, and aortic aneurysm can be
associated with a reduction of contractile VSMC number. Knock-
out of Dicer impairs miRNA biogenesis. In VSMCs, this induces
embryonic lethality, showing abnormal development of vascu-
lar vessels. These findings suggest that miRNAs play important
roles in proliferation, migration and phenotypic transformation
of VSMCs. MiRNAs are additionally involved in VSMC biology
and behavior, acting on cell apoptosis proliferation, and migra-
tion through modulating the expression of vasoactive molecules,
cytokines, MMPs and growth factors.
The miR-29 family of miRs contains three members (miR-
29a, miR-29b, and miR-29c) that are encoded by two separate
loci, giving rise to bi-cistronic precursor miRs (miR-29a/b1 and
miR-29b2/c). This family targets numerous gene transcripts that
encode ECM proteins involved in fibrotic responses, including
TABLE 1 | microRNAs which could be involved with aneurysmal disease.
MiRNA Up/down
regulation
Target genes Function regulated Expression sites References
miR143/145 Down Klf4, myocardin, Elk-1, Direct VSCM differentiation, repress
VSCM proliferation
Murine cardiac progenitors Mice
VSMCs
Cordes et al., 2009;
Elia et al., 2009
miR29 up ECM protein encoding genes
(COL1A1, COL1A2, COL3A1,
FBN1, ELN, MCL1, MMP2,
MMP9)
Regulate ECM Human aortic SMCs Murine models
of experimental AAA
Chen et al., 2012;
Maegdefessel et al.,
2012
miR 205 up TIMP3, RECK Regulate ECM Murine model of AAA Kim et al., 2014
miR 26a down SMAD-1 Promotes vascular SMC proliferation
while inhibitin g cellular differentiation
and apoptosis, and alters TGF-β
pathway signaling
Human aortic SMCs Leeper et al., 2011
miR 21 up PTEN Modulate proliferation and apoptosis
of VSMCs
Murine models of experimental AAA Maegdefessel et al.,
2012
miR 195 up ELN, different COL isoforms,
MMP2, MMP9
Regulate ECM Mouse aorta SMCs Zampetaki et al., 2014
miR
221/222
up p27, p57, c-Kit pro-proliferative, pro-migration, and
anti-apoptotic effects, Promote a
synthetic phenotype in VSMCs
Human aortic SMCs Aorta SMCs
and ECs from rats
Davis et al., 2009; Liu
et al., 2012
AAA, abdominal aortic aneurysm; c-kit, COL1A1, collagen type 1 alpha 1; EC, endothelial cell; ELK1, ETS domain-containing protein; ELN, elastin; FBN, fibrillin; KLF4, Kruppel-like
factor 4; MCL1, myeloid cell leukemia 1; MMP, matrix metalloproteinase; PTEN, phosphatase and tensin homolog; SMAD-1, mothers against decapentaplegic homolog 1; RECK,
reversion-inducing-cysteine-rich protein with kazal motifs; SMC, smooth muscle cell; TIMP3, metalloproteinase inhibitor 3; VSMC, vascular smooth muscle cell.
TABLE 2 | Long noncoding RNAs studied in vascular smooth muscle cells.
lncRNA Class Function regulated References
ANRIL NAT Influences VSMC function by regulating CDKN2A, CDKN2B, DAB2IP,
LRP1, LRPR, CNTN3 expression
Boucher et al., 2003; Elmore et al., 2009; Gretarsdottir et al.,
2010; Bown et al., 2011; Congrains et al., 2012
SENCR Antisense Inhibitis of VSMC migration Bell et al., 2014
LncAng362 Antisense Reduces VSMC proliferation Leung et al., 2013
HIF1A-AS1 Antisense Pro-apoptotic and anti-proliferative effect on VSMCs Wang et al., 2014
ANRIL, antisense non-coding RNA in the INK4 locus; SENCR, smooth muscle and endothelial cell-enriched migration/differentiation-associated lncRNA; HIF1A-AS1, antisense hypoxia
inducible factor 1 alpha anti sense RNA; NAT, natural antisense transcript; LRP1, low density lipoprotein receptor-related protein 1; LRPR, low density lipoprotein receptor; CDKN,
cyclin-dependent kinase inhibitors; DAB2IP, DAB2 interacting protein; CNTN3, contactin-3; VSMC, vascular smooth muscle cells.
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several collagen isoforms (e.g., COL1A1, COL1A2, COL3A1),
fibrillin-1, and elastin (ELN) (Boon et al., 2011).
Over-expression of miR-21 increases VSMC survival and
proliferation (Song et al., 2012). By contrast, miR-133 reduces
proliferation and migration of VSMC through repressing tran-
scription factor Sp-1 (Torella et al., 2011). MiR-133 is highly
expressed in the healthy vasculature, especially in VSMCs. It
is anti-proliferative and upregulated when VSMCs are qui-
escent. Overexpression of miR-133 reduced VSMC prolifera-
tion in vitro; while anti-miR-133 increased VSMC proliferation
(Torella et al., 2011). In vitro studies showed that ERK1/2 acti-
vation is partly responsible for miR-133 downregulation when
VSMCs are primed for the phenotypic switch (Zhan et al., 2003;
Torella et al., 2011).
MiR-143/145 have been extensively studied in vascular pathol-
ogy. This cluster alters the SMC phenotypic switch and its expres-
sion is decreased by acute and chronic vascular stress. The two
miRNAs cooperate in the regulation of VSMC fate and plastic-
ity by targeting several transcription factors, such as KLF4, KLF5
myocardin and Elk-1 (Boettger et al., 2009). A study of Cordes
et al. (2009) demonstrates the role of the miR-143/145 cluster in
VSMC differentiation and the repression of their proliferation.
Zampetaki at al focused on miR-195 in aortic aneurysmal dis-
ease, performing both in vitro and in vivo studies (Zampetaki
et al., 2014). In vitro experiments on murine VSMCs confirmed
the involvement of miR-195 in ECM homeostasis regulation.
Proteomic analyses on the conditioned medium from VSMCs
transfected with either pre-miR-195 or anti-miR-195 showed that
miR-195 expression is reversely correlated with elastin, a direct
target of this miRNA (Zampetaki et al., 2014). Elastin is fun-
damental for the maintenance of aortic mechanical integrity,
allowing the vessel to resume its shape after stretching or con-
tracting. Low elastin levels are typical of aneurysmal diseases.
Recently, Kim et al. showed miR-205 is upregulated in abdomi-
nal aortic endothelial cells (ECs) and miR-205 stimulates MMP
activity by targeting two endogenous MMP inhibitors, known
as tissue inhibitor 3 of MMP (TIMP3) and reversion-inducing
cysteine-rich protein with kazal motifs (RECK) (Kim et al.,
2014).
The role or miR-26a has been studied by Leeper and collab-
orators, working on human aortic SMCs. They performed sev-
eral assays to assess how transfection with either anti-miR or
pre-miR affected VSMCs behavior. The decrease in miR-26a lev-
els was associated with a reduction in VSMCs proliferation and
migration, and a significant increase of H2O2-induced apopto-
sis, in comparison to control cells. They demonstrate the targeted
action of this miR on SMAD-1 protein in VSMCs, and thus the
effects on TGB-β pathway. All these effects could be fundamental
in AA development (Leeper et al., 2011).
MiR-221/222 seems to have a cell specific effect in blood
vessels. In a study by Liu et al., SMCs and ECs were isolated
from murine aorta samples. The effects of miR-221/222 down-
regulation and upregulation were analyzed on each cell type
studying their proliferation, migration and apoptosis. ThesemiR-
NAs resulted to have a pro-proliferative, pro-migration and
anti-apoptotic effect on VSMCs, while an anti-proliferative,
anti-migration and pro-apoptotic effect on ECs. The action of
miR-221/222 are mediated by directly suppressing c-kit and
cyclin-dependent kinase inhibitors p27Kip1 and p57Kip2, three
proteins involved in key processes as cell differentiation, prolif-
eration, migration and apoptosis (Liu et al., 2012). miR-221/222
is up-regulated, while miR-133, miR-143/145, and miR-663 are
down-regulated in response to PDGF treatment on VSMCs (Liu
et al., 2012). MiR-221/222 is overexpressed in injured vascular
wall SMCs in rat carotid arteries after angioplasty. Specific knock-
down of miR-221 and miR-222 resulted in decreased VSMC pro-
liferation in vitro. Knockdown also suppressed VSMC prolifer-
ation in vivo and decreased neointimal lesion formation after
angioplasty in rat carotid arteries (Liu et al., 2010).
LncRNAs
As aforementioned, here we are reviewing the actions of a few
lncRNAs in vascular cell biology at large since specific studies on
lncRNAs in aneurysmal VSMCs are still lacking.We are confident
that this gap will be soon filled by the pioneer researchers who
have started lncRNA research programs in vascular medicine.
LncRNAs regulate gene expression, including chromatin
remodeling, mRNA transcription and processing, and post-
transcriptional pathways. It is important to explore whether
lncRNAs could be involved in vascular disease through these
mechanisms. Wang et al. showed that HIF1A-AS1 mediates the
pro-apoptosis and anti-proliferative responses induced by BRG1
gene (Brahma-related gene 1) in VSMCs (Wang et al., 2014).
They also showed that BRG1 expression is significantly increased
in the aortic media of TAA patients compared to the normal
group, implying that BRG1 may play a role in development
and progression of TAA. LncRNAs play critical roles in the reg-
ulation of cellular process such as cell growth and apoptosis
(Wang et al., 2014). BRG1 was knocked down in VSMCs and
a microarray was performed and the expression of HIF1A-AS1
was found to be regulated by BRG1. Overexpression of BRG1 in
TAA and the interaction between BRG1 and the lncRNA HIF1A-
AS1 in VSMCs might provide clues to the molecular mecha-
nisms involved in TAA. This should be pursued by using iso-
lated VSMCs from TAA patients and appropriate animal models
(Wang et al., 2014). The lncRNA HIF1A-AS1 plays an important
role in the pathophysiology of VSMCs.
The Natural antisense (NATs) ANRIL, KCNQ1OT, and
SENCR have been found expressed in VSMCs (Congrains et al.,
2012). ANRIL, as discussed elsewhere in this review, also regu-
lates the function of VSMCs. As explained below, the genomic
region (9p21) coding for ANRIL also contains the CDKN2A
and CDKN2B genes which encode the cell cycle regulators p16
(INK4a), p14 (ARF) and p15 (INK4b). The role of ANRIL
in various types of aneurysms needs to be investigated. The
9p21 genotype had an influence on CDKN2A/CDKN2B/ANRIL
expression levels in VSMCs, VSMC proliferation and VSMC con-
tent in atherosclerotic plaques. Analyses of VSMC primary cul-
tures showed that the 9p21 risk genotype was associated with
reduced expression of p16 (INK4a), p15 (INK4b) and ANRIL and
with increased VSMC proliferation (Congrains et al., 2012).
RNA sequencing (RNA-seq) by Bell et al. on the human
coronary artery SMCs showed 31 unannotated lncRNAs, includ-
ing SENCR, which is enriched in vascular cells. SENCR is
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transcribed antisense from the 5′ end of the FLI1 gene and
exists as two splice variants (Bell et al., 2014). SENCR has a
cytoplasmic location (Bell et al., 2014). RNA-seq experiments
in VSMCs after SENCR knockdown revealed decreased expres-
sion of myocardin and numerous smooth muscle contractile
genes, while several promigratory genes were increased. Loss-of-
function studies in scratch wound and Boyden chamber assays
suggests SENCR as an inhibitor of VSMC migration (Bell et al.,
2014).
Finally, several lncRNAs (Lnc Ang362, Lnc-Ang 162, LncAng
112, LncAng249, and LncANg219) were found to be expression-
ally regulated by Ang II in VSMCs (Leung et al., 2013). The
lncRNA AngII362 also mediates the proliferation of VSMC by
acting on the miR221/222 (Leung et al., 2013).
In vivo Aneurysm Models
In order to develop knowledge of ncRNAs that can be trans-
lated to clinical applications, it is important to devise “repro-
ducible” models mimicking the features of human aneurysms,
such as lesion in the elastic layer, inflammatory infiltrate within
the adventitial and medial layers, and increased proteolytic activ-
ity within the aneurysm wall. Clinical relevant models of AA are
still lacking, particularly for TAA. Consequently, there is large
scope for improvement, as discussed below.
One of the first animal models employed for aneurysm stud-
ies is the blotchy mouse (Andrews et al., 1975). These mice
have a mutation (blotchy allele) in the Mottled locus gene of
the X chromosome, which leads to cross-linking abnormalities
in elastin and collagen. These mice have a variety of connective
tissue abnormalities, including spontaneous thoracic aneurysm
formation and reduce tensile strength of the skin (Andrews et al.,
1975). Aneurysms in this model are histopathologically similar
to that observed in humans, with elastic fiber fragmentation and
inflammatory infiltrate within the medial and adventitial layers
(Andrews et al., 1975). To the best of our knowledge, this mouse
model has not been employed for ncRNA studies. By contrast,
another genetic model, the Fibulin-4(R/R) mice have been used
for studying miR-29 expression by Boon et al. (2011). Fibulin
proteins form bridges that stabilize the organization of extracel-
lular matrix structures (Hanada et al., 2007). Hanada et al. have
shown that reduced Fibulin-4 expression leads to dilatation of
the ascending aorta, aneurysm formation, dissection of the aor-
tic wall and thickened aortic valvular leaflets that are associated
with aortic valve stenosis and insufficiency (Hanada et al., 2007).
At the expressional level, the TGF-beta signaling appears per-
turbed (Hanada et al., 2007). Taken together, these pathological
and expressional features suggest the relevance of Fibulin-4(R/R)
for aneurysmal studies.
Mice with an homozygous Apolipoprotein E gene depletion
(ApoE KO) are also predisposed to elastic fiber fragmentation
as well as to atherosclerosis and atherosclerotic plaque forma-
tion (Anidjar et al., 1990). In addition to these genetic models,
the delivery of exogenous substances has also been employed to
trigger AAA in mice. Examples are the perivascular delivery of
calcium chloride or proteases (collagenases and elastases), tran-
sient perfusion of elastase into infrarenal aorta, and prolonged
systemic Ang II infusion (Daugherty and Cassis, 2004). These
interventions can have been performed either in wild type mice
or in atherosclerotic ApoE KO (Azuma et al., 2009).
One study investigated the role on miR-21 and miR-29 in
mice with AAA (Maegdefessel et al., 2014a). They noted that
miR-21 was associated with protective qualities against AAA
development. They took antagomiR against miR-21 and lentiviral
vector (LV) of pre-miR-21, which would down-regulate and up-
regulate miR-21, respectively.With the antagomiR-21, they noted
a marked increase in the development of AAA in murine mod-
els, whereas LV-mediated miR-21 overexpression significantly
decreases AAA progression. Interestingly, they also noted that
in samples that were exposed to high levels of nicotine to sim-
ulate the modifiable risk factor of smoking, there was a marked
increase in miR-21, and eluded to the fact that this may be a
“safety mechanism,” in order to try and combat the negative
effects of smoking (Maegdefessel et al., 2014a). In a different
studies, The miR-21 was shown to prevent abdominal aortic
aneurysms development by targeting PTEN (phosphatase and
tensin homolog) (Ji et al., 2007). MiR-21 regulates growth and
survival of VSMCs by decreasing the expression of PTEN and
inducing expression of Bcl-2, resulting in pro-proliferative and
anti-apoptotic effects in a carotid injury model in rats. In regards
to aortic dilatation, miR-21 was significantly up-regulated in two
established murine models of AAA disease. Among the miR-21
target genes that alter proliferation and apoptosis, PTEN was the
only target gene to be significantly down-regulated at three dif-
ferent time points during aneurysm development and progres-
sion. miR-21 also targets multiple members of the dedicator of
cytokinesis (DOCK) superfamily and modulates the activity of
ras-related C3 botulinum toxin substrate 1 (Rac1) small GTPase
that regulates VSMC phenotype (Ji et al., 2007).
The role of miR-29 in aneurysm formation and development
of aortic dilation was confirmed by Maegdefessel et al. (2012).
MiR-29 is known to be involved in the regulation of ECM within
the vascular wall. Consequently, increased miR-29 expression
would down-regulate ECM synthesis. In aneurismal formation,
an increase in ECM is a protective quality, an attempt to increase
the tensile strength of the vessel in order to prevent diameter
expansion. The miR-29 family, which targets numerous gene
transcripts that encode ECM proteins, is known to modulate
gene expression during development and aging of the abdomi-
nal aorta and during the progression of aortic aneurysms (Boon
et al., 2011; Maegdefessel et al., 2012, 2014a). Maegdefessel et al.
(2012, 2014a) looked in particular at miR-29b, one of the fam-
ily members of miR-29. In their murine models, they noted that
there was an increase in ECM production when they inhib-
ited miR-29b expression in their antimiR-29 mouse population.
In addition to this, they also noted a concurrent decrease in
MMP2 andMMP9. These findings were also seen in their human
aneurysm/non-aneurysm tissue studied. This suggests a strong
link with increased miR-29b expression and aneurismal develop-
ment (Maegdefessel et al., 2014a). Interestingly, similar findings
were also found by another team: Boon et al. (2011) looked at
miR-29b in association with aneurysm formation and increasing
age. Age is a significant risk factor for the development of AAA
disease. They noted that vascular wall changes due to age are cru-
cial to the development of AAA disease. In their study they found
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increased levels of miR-29 in aging vessel walls. Knowing that
miR-29 is associated with reduced ECMproduction and therefore
increased AAA development, they inferred from their results that
the age related risks associated with AAA development were due
to increased miR-29 levels and reduced wall structural integrity
(Boon et al., 2011). Inflammation is another key element in the
AAA development and disease progression as it has strong corre-
lations with vessel reconstruction and alteration (Shimizu et al.,
2006). One study noted that miRNA expression may be linked
to inflammatory responses within vasculature, in turn, affecting
AAA development (Maegdefessel et al., 2014b). They looked at
miR-23b-24-27b cluster in murine models, and attempted to find
a correlation with up-regulated inflammatory mediators. They
found that miR-24 had the most significant negative correlation
with inflammatory mediators, looking in particular at chitinas 3-
like1 (CH3L1). CH3L1 is a known mediator of inflammation and
has been suggested as a novel biomarker of chronic inflamma-
tory disease (Lee et al., 2011). They found that in murine AAA
models miR-24 levels are inversely correlated with increased lev-
els of CH3L1. Inferring from these results, we can speculate that
miR-24 not only has protective qualities against the inflamma-
tory processes involved in AAA disease, but it may also be used
as a biomarker for the progression of the disease. Nonetheless,
there were no significant changes in circulating miR-24 between
small and large AAA. However, CH3L1 levels were significantly
increased in large AAA compared with small, and that using both
in conjunction may be a viable biomarker of disease progression
(Maegdefessel et al., 2014b). These results were noted to correlate
to those in ex-vivo human AAA tissue.
Finally, miR-712 is the murine homolog of the aforemen-
tioned MMP activator miR-205 (Kim et al., 2014). In addition,
miR-712 was proved involved with aneurysm formation in mice
(Kim et al., 2014).
Concerning lncRNAs, the aforementioned Lnc Ang362, Lnc-
Ang 162, LncAng 112, LncAng249, and LncANg219 were found
to have altered expression altered in the aorta of Ang II treated
mice (Leung et al., 2013).
Research has timidly expanded to large animal models, which
better mimic the human anatomy and allow for diagnostic
(including in vivo imaging) and therapeutic approaches similar
to what could be delivered to human patients. One study in par-
ticular looked at the use of porcine arterial tissues that have been
in vivo manipulated with a mixture of collagenases and calcium
chloride in order to replicate TAA as close as possible to the
ones observed in patients (Eckhouse et al., 2013). Eckhouse et al.,
reproduced this model and demonstrated that under the condi-
tions they used the outcome was predictable and consistent. In
addition to this, they cited the importance of finding a largemam-
malian model that will accurately mimic human pathology. They
propose that murine models previously used in TAA studies are
only useful at the cellular level, as this data is not easily trans-
ferable to human models. We concur with this opinion. Their
porcine model, on the other hand, was noted to have the mural
structure and contents that are seen in human TAA tissue stud-
ies, i.e., cell contents, wall constituent configuration and protease
levels (in particular MMPs). The importance of this study is that
the development of a reproducible TAAmodel that can be used in
any study, providing a level of standardization and transferabil-
ity to the disease in humans (Riches et al., 2013).We are currently
developing themodel to be used in our own translational research
projects.
Ex-vivo Aneurysm Models
A recent study co-authored by one (TGA) of us, used porcine
arterial segments to create an ex-vivomodel of aneurysm compa-
rable to human AAA. Freshly isolated porcine arteries were pre-
treated with collagenase and elastase before being cultured under
flow in a bioreactor for 12 days. This produced aneurysmal-like
remodeling. VSMCs were harvested from the porcine aneurysmal
vessels and further studied in vitro in comparisons with cells pre-
pared from human end stage AAA disease. Cellular senescence
was investigated using β-galactosidase staining and apoptosis was
quantified using a fluorescence-based caspase 3 assay. The data
on VSMC morphology, senescence and proliferation were com-
parable to that of end stage human AAA vessels (Riches et al.,
2013). The authors propose this model can be used to examine
temporal changes in VSMC biology in porcine and also human
aortic vessels and to identify the molecular mechanisms conduc-
tive to or protective from aneurysmal remodeling (Riches et al.,
2013). In the longer term, this may inform and functionally val-
idate new therapeutic targets (including miRNAs and lncRNAs)
as part of a translational pipeline preceding human interventional
studies.
Work on Clinical Samples and Patient Population
In recent years miRNAs have been found to regulate vascular
pathologies in aortic aneurysm (thoracic and abdominal disease).
Expressional Studies
Liao et al. performedmicroarray and systemic analysis of miRNA
from the ascending aorta segments of TAA patients and normal
aorta from organ donors (Liao et al., 2011). The resulting miR-
NAs were validated by qPCR and target genes were predicted
TargetScan v5.1 and Mirind V5.1. The miRNAs which were
validated as significantly upregulated in human TAA are miR-
183∗, −433, −553, −491-3p, −30c, and −338-5p. By contrast,
miR-143, −145, −22, −24, −93 and −768-5p were lower in the
TAA samples (Liao et al., 2011). Elia et al. also found that miR143
and 145 are down regulated in ascending aortic aneurysms (Elia
et al., 2009). Loss of miR-143 and miR-145 expression induces
structural modification of the aorta due to an incomplete dif-
ferentiation of VSMC. This confirms a previous study which
showed transition of VSMC from contractile to synthetic pheno-
type exists in media of TAA aorta, indicating that VSMC are less
differentiated in TAA (Elia et al., 2009).
In another study, Jones et al. compared miRNA expres-
sion levels in aortic tissue specimens collected from patients
with ascending TAAs and looked at the aneurysm progres-
sion (Jones et al., 2011). They observed decreased expression of
miRs −1, −21, −29a, −133a, and −486 as compared with nor-
mal aortic specimens. A significant relationship between expres-
sion of miR-1, −21, −29a, and −133a and aortic diameter was
identified; as aortic diameter increased, miR expression decreased
(Jones et al., 2011). Through the use of a bioinformatics approach,
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members of the matrix metalloproteinase (MMP) family, pro-
teins involved in TAA development, were examined for putative
miR binding sites. MMP2 and MMP9 were identified as poten-
tial targets for miR-29a and miR-133a, respectively, and MMP-2
was subsequently verified as a miR-29a target in vitro (Jones et al.,
2011). Reduced miR29-b was also replicable in human aneurys-
mal tissue samples compared with controls (Maegdefessel et al.,
2012).
Kumari et al. compared ascending TAA with descending TAA
tissue using miRNA microarray and found that the expression
level of miR-1, 30c-2∗, miR-145, miR-204, miR-331-3p were up-
regulated in ascending TAA in comparison with descending TAA
(Premakumari et al., 2014). Importantly this data suggests that
these miR mayhave biological and clinical relevance in the con-
text of TAAs and may provide significant targets for diagnos-
tic/prognostic and therapeutic applications (Premakumari et al.,
2014).
Pahl et al. compared miRNA expression levels using an
affymetrix GeneChip miRNA array in human AAA vs. control
human aorta tissue (Torella et al., 2011). Three miRNA were
found upregulated in AAA: miR 181a∗, miR 146a, miR21. While
five miRNA miR 133b, miR 133a, miR 331-3p, miR 30c-2∗, and
miR204 were significantly down regulated in human AAA tissue.
The down regulated miRs replicated well in the qPCR validation
while the upregulated three miRs failed to replicate. In addition,
they found that miR 133 is down regulated in human AAA tissue
(Torella et al., 2011).
LncRNA expression has not yet been investigated in clinical
samples. However, we expect that this gap will be soon filled,
including by our group. Because of the high number of lncRNAs,
next generation sequencing methods will be useful in developing
these studies.
Genetic Studies
Genome-wide association studies (GWAS) is an approach used to
identify associations between single nucleotide polymorphisms
(SNP), variations in a single nucleotide within theDNA sequence,
and their influence on health and disease. AA is a complex dis-
ease with important risk factors like male sex, cigarette smoking,
a personal history of myocardial infarction and a heritability of
70% i.e., family history (Wahlgren et al., 2010). GWAS suggest a
role of ANRIL in AA. There are five chromosomal regions in the
human genome with the strongest supporting evidence of con-
tribution to the genetic risk for AAA: (1) ANRIL (also known as
CDKN2BAS) on chr9p221 locus is expressed in humans. 9p21.3.
This locus is among the most strongly replicated regions for car-
diovascular disease and is also associated with coronary artery
disease. ANRIL encodes an antisense lncRNA that regulates
expression of the cyclin-dependent kinase inhibitors CDKN2A
and CDKN2B; (Congrains et al., 2012) (2) DAB2 interacting
protein (DAB2IP), which encodes an inhibitor of cell growth
and survival; (3) low density lipoprotein receptor-related pro-
tein 1 (LRP1), a plasma membrane receptor involved in VSMC
and macrophage endocytosis; (4) low density lipoprotein recep-
tor (LRPR); and (5) contactin-3 (CNTN3) (Boucher et al., 2003;
Elmore et al., 2009; Gretarsdottir et al., 2010; Bown et al., 2011).
Candidate gene studies represent complementary approaches
to analyze genetics behind AA. The most significant associations
with AAA discovered in candidate gene studies are: (1) SORT1
(lipid metabolism) (Jones et al., 2013); (2) IL6R (inflammation)
(Harrison et al., 2013); (3) LPA (lipid metabolism); (4) AGTR1
(Renin angistenin system) (Jones et al., 2008); (5)TGFBR2 (TGFB
signaling) (Biros et al., 2011); (6) MMP3 (Degradation of ECM)
(Yoon et al., 1999); (7)MTHFD1 (methionine metabolism) (Hin-
terseher et al., 2011); (8) LRP5 (lipid metabolism) (Boucher et al.,
2003). To date, genetic studies targeting ncRNAs are lacking.
Summary and Future Research
Today, there are no clinical tests to detect an aneurysm and
the management of aneurismal diseases is unsatisfactory. Surgi-
cal intervention is the only valuable treatment option and based
only on size. Predictors of biological behavior of an aneurysm
wall would enhance the management of aneurysm disease from
a one dimensional surgical strategy. This strong clinical need has
prompted the research of new biomarker and therapeutic targets
to be to translate into clinical care. The explosion on miRNA
research in the last year delivered some candidates to be further
studied. Basic science still needs to fill several gaps. Firstly, stud-
ies in ncRNA biology have focused on the effects of miRNAs or
lncRNAs on VSMC and ECs. This research needs to be extended
to include miRNAs or lncRNAs in other cellular components of
blood vessels, such as fibroblasts and macrophage, which remain
to be investigated. NcRNA research focused on their function in
blood vessels is currently limited. In addition to miRNAs and
lncRNAs, other ncRNAs, such as rasiRNAs and piRNAs, may also
be involved in the development of cardiovascular pathology, and
their function requires evaluation. Additional work on miRNA
drug chemistry and delivery approaches enabling local and sys-
temic but safe delivery of ncRNA-based therapeutics is required,
this further necessitates the use of clinical relevant animal mod-
els and in vivo imaging systems. lncRNAs are vastly unexplored
by cardiovascular researchers, but given the enthusiasm of many
academic and industry-based scientists who specialize in ncRNAs
research, we foresee this will be reversed by a plethora of exciting
studies.
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